- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Heather Cheng presents the importance of lifestyle and prevention of complications in advanced prostate cancer, focusing on how we should take care of our patient’s muscle strength. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle Cancer Care Alliance Prostate Cancer Genetics Clinic, Division of Medical Onco...
|
- Details
- Sigrid Carlsson joins Phillip Koo in a discussion on Smart Screening in Prostate Cancer, a session being highlighted at the upcoming 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer taking place virtually September 22-24. The pair discuss challenges with screening today that require clinicians to be smarter about screening including the risk of overdiagnosis, incorporating...
|
- Details
- Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...
|
- Details
- Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...
|
- Details
- Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...
|
- Details
- Phillip Koo is joined by Faina Shtern, president of the AdMeTech Foundation. AdMeTech Foundation was established as a Nonprofit Corporation for the Advancement of Medical Technologies, with a priority focus on the advancement of prostate cancer care, in November 1997. Dr. Shtern provides the background of how and why this foundation was started and Drs. Koo and Shtern discuss the foundation's role...
|
- Details
- Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on a subgroup analysis of the HERO trial assessing the efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer based on baseline body mass index (BMI). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Cent...
|
- Details
- Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Divisi...
|
- Details
- Oliver Sartor is joined by Alicia Morgans to discuss her presentation at the GU ASCO 2022 Annual Meeting on the largest digital survey conducted in patients with prostate cancer, the initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis...
|
